Increasing Semaglutide: What the Evidence Says About Dose Escalation

What the trial data established about the escalation schedule

The STEP programme didn't invent the titration schedule arbitrarily. Semaglutide slows gastric emptying and acts on appetite-regulating centres in the brain; both effects intensify as the dose rises, which is precisely why the body needs time to adjust at each level before moving higher. The STEP 1 trial built in roughly four weeks per dose step (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg) and the nausea, vomiting and digestive discomfort recorded in participants was heavily concentrated in the early weeks of each new dose, easing considerably once the body settled. That pattern is now baked into the licensed schedule. It's also the reason the 0.25 mg starting dose isn't expected to produce meaningful weight loss on its own; it's there to prepare your system, not to treat. The NHS semaglutide medicines page describes the standard titration clearly and is worth reading alongside your Patient Information Leaflet.

Reaching 2.4 mg matters. The trial data show that weight loss continues to accumulate as the dose rises, with the largest reductions coming at the maintenance level. Stopping the escalation early because of manageable side effects, rather than because a prescriber has judged a lower dose sufficient, generally means leaving results on the table.

When increasing semaglutide should slow down or pause

The four-week intervals are a minimum, not a deadline. If you find a particular dose step difficult (persistent nausea that is affecting your ability to eat or function, or frequent vomiting) your prescriber may recommend staying at the current level for another four weeks before attempting the increase. This isn't a failure; it's the schedule working as intended. How Wegovy increments are managed in practice is a question our prescribers hear regularly, and the honest answer is that tolerability sits alongside efficacy in the clinical assessment.

There are also circumstances where an increase should be paused entirely until you've spoken to your prescriber: severe or persistent stomach pain (particularly pain that radiates toward the back), signs of dehydration from prolonged vomiting or diarrhoea, or a planned surgical procedure. The MHRA's January 2026 Drug Safety Update on GLP-1 medicines highlighted acute pancreatitis as a serious, though infrequent, side effect, severe abdominal pain in this context warrants prompt medical attention, not waiting for your next scheduled review. For a fuller picture of what to watch for at each dose stage, the semaglutide overview covers the side-effect profile in detail.

Does everyone need to reach the maximum dose?

Not necessarily, though 2.4 mg is where the evidence for weight management is strongest. A small number of people lose sufficient weight at a lower maintenance dose, and a prescriber may judge that staying there is appropriate if results are good and tolerability is a concern. The licensed guidance does note that if less than 5% weight loss is achieved after six months at the maintenance dose, continuing treatment should be reconsidered, so the direction of travel for most people is upward, steadily.

The approved 7.2 mg dose, cleared by the MHRA in early 2026, represents a further step beyond 2.4 mg for eligible adults with obesity (BMI 30 or above). The dedicated single-dose 7.2 mg pen was approved on 14 April 2026; trial data reported around 20.7% average weight loss over 72 weeks at this level, narrowing the gap with tirzepatide results. Whether that higher dose is appropriate is a clinical decision. You can read more about Wegovy's full licensed profile if you're weighing up your options.

If you're wondering whether you're expected to keep increasing indefinitely, the short answer is no, the question of whether dose increases are mandatory is answered in more detail in its own page, but the guiding principle is that escalation serves the treatment goal, not the other way around.

What increasing semaglutide means for your prescription

In the UK, semaglutide is a prescription-only medicine. Every dose change requires a prescriber's authorisation, this isn't bureaucracy for its own sake. The clinical review before each increase is the mechanism that catches problems early: an unresolved side effect, a change in your health, a medicine interaction that matters more at higher doses. It's also the point at which your prescriber checks that the treatment is delivering results consistent with continuing.

At nume, every repeat order is reviewed individually by a GPhC-registered Independent Prescriber before dispatch. There's no subscription that rolls forward automatically; evidence of your current treatment and response forms part of that assessment. If you're thinking about what using semaglutide looks like week to week, that page gives a practical picture of the routine. And for a sense of how effective semaglutide is across different doses, the evidence summary there is grounded in the same trial data cited above.

Private treatment pricing (including what a complete prescription service should realistically include) is covered on the Wegovy cost page, which puts the numbers in honest context. When you're ready, you can check your eligibility with our prescribers at no charge.